Recent News

• 12.09.2025 - Clinical Outcomes of Emavusertib Added to Azacitidine and Venetoclax Combination Therapy ASH 2025
• 12.09.2025 - Curis Provides Updated Data from its Frontline AML Triplet Study
• 11.24.2025 - Secondary CNS Lymphoma Clinical Outcomes SNO 2025 Poster
• 11.24.2025 - TakeAim Lymphoma Molecular Profiling and CNS Penetration SNO 2025 Poster
• 11.24.2025 - TakeAim Lymphoma Clinical Outcomes SNO 2025 Poster
• 11.14.2025 - Curis to Present at Upcoming 30th Annual SNO Meeting
• 11.06.2025 - Curis Provides Third Quarter 2025 Business Update
• 10.30.2025 - Curis to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on November 6, 2025
• 10.06.2025 - Emavusertib in Combination with Gemcitabine and Nab-paclitaxel in Metastatic or Unresectable Pancreatic Ductal Adenocarcinoma AACR 2025 Poster
• 10.03.2025 - Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Recent Filings

• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.13.2025 - 8-K/A Current report
• 11.06.2025 - 8-K Current report
• 11.06.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 11.06.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.06.2025 - EX-99.1 EX-99.1
• 10.24.2025 - 8-K Current report
• 08.22.2025 - 8-K Current report
• 08.18.2025 - EFFECT Notice of Effectiveness